Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Awards
Green Chemistry Awards to Bristol Myers Squibb, Merck & Co., and PharmaBlock Sciences
by Nina Notman, special to C&EN
July 9, 2023
| A version of this story appeared in
Volume 101, Issue 22
Credit: Brad Zangwill Photography
From left: Richard Fox (Bristol Myers Squibb), Zara Seibel (Codexis, who worked on the Bristol Myers Squibb project), Zhenzhen Dong (PharmaBlock Sciences), John McIntosh (Merck & Co.), and Feng Peng (Merck & Co.) collected their awards at the Green Chemistry and Engineering Conference, held June 13–15.
The American Chemical Society Green Chemistry Institute Pharmaceutical Roundtable has announced that teams at Bristol Myers Squibb and Merck & Co. have won its 2023 Peter J. Dunn Award for Green Chemistry and Engineering Impact and that PharmaBlock Sciences has won its 2023 Contract Manufacturing Organization (CMO) Excellence in Green Chemistry Award.
The Bristol Myers Squibb team is recognized for developing an enzymatic route to install two stereocenters on the cyclohexyl ring of BMS-986278, a lysophosphatidic acid receptor 1 antagonist in clinical trials as a treatment for lung fibrosis.
The Merck & Co. team is recognized for developing new organo- and bio-catalysis bond-forming strategies to the cyclic dinucleotide MK-1454, a stimulator of interferon genes agonist in clinical trials as a treatment for solid cancers and lymphomas.
PharmaBlock Sciences is recognized for an innovative continuous manufacturing process for 3-oxo cyclobutane-1-carboxylic acid, an intermediate used in several marketed drugs and drug candidates.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter